Home / Treatments / Tesamorelin / Evidence
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Prices verified October 15, 2026·Methodology v4.1

Tesamorelin: what the human evidence actually shows

Direct answer

Tesamorelin is a GHRH analogue and — importantly — one of the few peptides in this category that is <b>genuinely FDA-approved</b>, though for a narrow indication: the reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It is marketed as Egrifta. Everything else it is sold for is off-label.

What the evidence actually shows

The approval rests on real randomised trial data showing a meaningful reduction in visceral adipose tissue in the HIV-lipodystrophy population, with associated improvements in triglycerides. That evidence is good.

It is also specific. There is no comparable trial evidence for tesamorelin as a general fat-loss or longevity treatment in people without HIV-associated lipodystrophy, and effects were shown to reverse when treatment stopped. A drug being FDA-approved for something is not evidence that it works for something else.

Three ways evidence gets overstated hereThree moves recur constantly in this category, and once you can name them you will see them everywhere. Mouse-to-human transfer: a striking longevity result in mice, presented as though it applies to you. Biomarker-for-outcome substitution: a study shows a blood level rose, and the marketing implies you will feel better or live longer. Deficiency-to-enhancement transfer: a treatment that helps people with a diagnosed deficiency is sold to healthy people seeking optimisation. None of these are valid inferences.

Frequently asked questions

What does Tesamorelin cost through telehealth?

We have not verified a market price. On October 15, 2026, the Egrifta WR website published no list price, describing co-pay and patient assistance programs instead, and Oak Longevity priced tesamorelin only after an assessment. Ask for the total cost in writing, and ask whether you will get Egrifta WR or a compounded product.

Is Tesamorelin FDA-approved?

Yes, for one use. Egrifta WR is approved to reduce excess abdominal fat in HIV-infected adults with lipodystrophy, and its label says it is not indicated for weight-loss management. Compounded tesamorelin is not the approved product, and other uses are off-label.

Does Tesamorelin work?

FDA approved Egrifta WR on clinical trial evidence in adults with HIV and lipodystrophy. We found no comparable trials for general fat loss, anti-ageing or performance in other people, and approval for one condition is not evidence for another.

Sources

  1. U.S. Food and Drug Administration — approved labels and compounding guidance for this molecule.
  2. PubMed / NIH — indexed human clinical literature.
  3. ClinicalTrials.gov — registered trials, where they exist.
  4. Our source hierarchy and pricing-verification methodology.

Spotted an error? Submit a correction.

Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed ByDr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.